MedTrace Logo

Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

NCT04557306 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-04-08

No results posted yet for this study

Summary

The objective of the study is to evaluate tolerability and safety of CBT101 in patients who underwent curative surgery and adjuvant therapy for solid cancer

Conditions

Interventions

BIOLOGICAL

CBT101 cells, every 2 weeks

CBT101 cells, every 4 weeks

BIOLOGICAL

CBT101 cells, every 4 weeks

CBT101 cells, every 4 weeks

Sponsors & Collaborators

  • CHABiotech CO., Ltd

    lead INDUSTRY

Principal Investigators

  • Chan Kim · CHA Bundang Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-10-26
Completion
2021-10-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04557306 on ClinicalTrials.gov